These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38751227)

  • 41. Allosteric Antagonism of the A
    Gao ZG; Toti KS; Campbell R; Suresh RR; Yang H; Jacobson KA
    Cells; 2020 May; 9(5):. PubMed ID: 32408534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
    Nimczick M; Decker M
    ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands.
    Bird MF; McDonald J; Horley B; O'Doherty JP; Fraser B; Gibson CL; Guerrini R; Caló G; Lambert DG
    PLoS One; 2022; 17(1):e0260880. PubMed ID: 35061679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.
    Dietis N; Guerrini R; Calo G; Salvadori S; Rowbotham DJ; Lambert DG
    Br J Anaesth; 2009 Jul; 103(1):38-49. PubMed ID: 19474215
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biased Opioid Ligands.
    Faouzi A; Varga BR; Majumdar S
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32948048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
    Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in G protein-coupled receptor allostery: from function to structure.
    Christopoulos A
    Mol Pharmacol; 2014 Nov; 86(5):463-78. PubMed ID: 25061106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bitopic muscarinic agonists and antagonists and uses thereof: a patent evaluation of US20160136145A1.
    Holzgrabe U; Decker M
    Expert Opin Ther Pat; 2017 Feb; 27(2):121-125. PubMed ID: 27967250
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction.
    Root-Bernstein R
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bitopic ligands: all-in-one orthosteric and allosteric.
    Kamal M; Jockers R
    F1000 Biol Rep; 2009 Oct; 1():77. PubMed ID: 20948611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors.
    Portoghese PS; Larson DL; Sayre LM; Yim CB; Ronsisvalle G; Tam SW; Takemori AE
    J Med Chem; 1986 Oct; 29(10):1855-61. PubMed ID: 3020244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current Advances in Allosteric Modulation of Muscarinic Receptors.
    Jakubik J; El-Fakahany EE
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32085536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
    Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
    J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
    Keov P; Sexton PM; Christopoulos A
    Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor.
    Del Giudice MR; Borioni A; Bastanzio G; Sbraccia M; Mustazza C; Sestili I
    Eur J Med Chem; 2011 Apr; 46(4):1207-21. PubMed ID: 21330016
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural Insights Accelerate the Discovery of Opioid Alternatives.
    Che T; Roth BL
    Annu Rev Biochem; 2021 Jun; 90():739-761. PubMed ID: 33756098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel Xanomeline-Containing Bitopic Ligands of Muscarinic Acetylcholine Receptors: Design, Synthesis and FRET Investigation.
    Matera C; Kauk M; Cirillo D; Maspero M; Papotto C; Volpato D; Holzgrabe U; De Amici M; Hoffmann C; Dallanoce C
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and opioid receptor affinity of bivalent ligands derived from 3,8-diazabicyclo(3.2.1)octanes.
    Barlocco D; Fadda P; Fratta W
    Farmaco; 1993 Mar; 48(3):387-96. PubMed ID: 8391821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.
    Burford NT; Clark MJ; Wehrman TS; Gerritz SW; Banks M; O'Connell J; Traynor JR; Alt A
    Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10830-5. PubMed ID: 23754417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products.
    Hou T; Xu F; Peng X; Zhou H; Zhang X; Qiu M; Wang J; Liu Y; Liang X
    J Ethnopharmacol; 2021 Apr; 270():113872. PubMed ID: 33485984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.